Louise Koopman
Associate Director, Translational Research Genmab
Louise Koopman, PhD, is Associate Director, Translational Medicine & Research at Genmab, where she leads preclinical and early clinical translational research supporting the development of next-generation T-cell–targeting antibody therapeutics. Prior to joining Genmab, Louise held research positions at Celgene, the Dana-Farber Cancer Institute, and Biogen, where she advanced novel antibody and small-molecule therapeutics from discovery through IND-enabling research. She holds an MSc in Bio-Pharmaceutical Sciences and a PhD in Tumor Immunology and Pathology from Leiden University, and completed postdoctoral research in immunology at Harvard University.
Seminars
Thursday 10th December 2026
Panel Discussion: Navigating Preclinical, Translational & Clinical Bottlenecks by Evaluating Key Learnings to Accelerate TCEs Towards Approval
3:30 pm
- How to improve preclinical models to better predict activity, clinical safety and de-risk translation into the clinic?
- How are next-generation preclinical platforms (e.g. organoids, humanised models, ex vivo systems) enabling evaluation of conditional activation and masking strategies?
- How can translational biomarker strategies, including antigen density thresholds and T-cell fitness profiling, improve patient stratification and clinical signal prediction?
- What will regulators most want to see before they are comfortable with first-in-human studies in these settings?
Thursday 10th December 2026
Fine-Tuning T-cell-Targeting Therapies Through Affinity Engineering & Dosing Strategy
4:00 pm
- Optimisation strategies for T-cell–targeting modalities: CD3 affinity modulation in T-cell engagers and dosing adaptation for T-cell co-stimulatory bispecific antibodies to improve benefit–risk, T-cell fitness and durability
- Comparative studies of two B7-H4 CD3 bispecific antibodies show that lower CD3 affinity reduces tumor cell killing and cytokine secretion while improving tolerability in cynomolgus monkeys
- Clinical acasunlimab + pembrolizumab data reveal less frequent dosing promotes T-cell rest and improves anti-tumor immune responses
